ESPR — Esperion Therapeutics Inc.

Ownership history in WASATCH ADVISORS LP  ·  51 quarters on record

This page tracks every 13F SEC filing in which WASATCH ADVISORS LP reported a position in Esperion Therapeutics Inc. (ESPR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.73% (2015 Q1)
Avg. % of fund
0.27%
First filed
2013 Q2
Last filed
2025 Q4
Quarters held
51
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 9,445,759 +2,383,902 +33.8% 0.21% $34.9M $3.70
2025 Q3 REDUCED 7,061,857 -3,278,404 -31.7% 0.10% $18.7M $2.65
2025 Q2 REDUCED 10,340,261 -590,996 -5.4% 0.05% $10.2M $0.98
2025 Q1 REDUCED 10,931,257 -13,551,001 -55.4% 0.09% $15.7M $1.44
47 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ESPR price (monthly, adj. close)

Other funds also holding ESPR

As of 2025 Q4 — sorted by position size

AIGH Capital Management LLC 3Y 3.58% Velan Capital Investment Management LP 3Y 2.6% PenderFund Capital Management Ltd. 3Y 7Y 2.56% Two Seas Capital LP 3Y 0.91% Eversept Partners, LP 3Y 7Y 0.72% nVerses Capital, LLC 0.56% ORBIMED ADVISORS LLC 3Y 7Y 0.45% Summit Wealth Group, LLC 3Y 0.29% Virtus Investment Advisers, LLC 3Y 7Y 0.18% Diametric Capital, LP 3Y 7Y 0.17%
← Back to WASATCH ADVISORS LP Holdings